Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-11-04 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
第二届董事会第二十六次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It details the convening of the meeting, attendance, agenda items discussed, and voting results on various corporate matters such as external financing by a subsidiary, changes in investment projects, related party transactions, and the scheduling of a shareholders' meeting. The document does not contain financial statements or detailed financial analysis but rather reports on board decisions and approvals. It is not an annual or interim report, earnings release, or audit report. It is also not a proxy statement or voting results announcement from a shareholders' meeting, but specifically a board meeting resolution announcement. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters and it is a full announcement, not a brief notice of report publication or certification, so it is not RPA or RNS.
2018-11-04 Chinese
关于监事辞职及增补监事候选人的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of a company supervisor and the nomination of a new supervisor candidate. It details the resignation of the current supervisor, the legal and regulatory compliance related to the resignation, and the nomination of a new candidate for the supervisory board. There are no financial statements, earnings data, or report publications. The content focuses on changes in the company's supervisory board, which falls under management or board information disclosures. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not a report or announcement of a report publication, so it is not RPA or RNS.
2018-11-04 Chinese
关于公司控股子公司获得外部融资的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding a financing transaction involving the company's controlling subsidiary obtaining external financing through issuance of preferred shares. It includes specifics about the transaction, approval processes, parties involved, financial data of the subsidiary, and risk disclosures. The content focuses on capital raising activities and financing arrangements rather than financial results, management changes, or regulatory filings. The document length is over 6,000 characters and contains substantive details about the financing deal. Therefore, it fits the category of Capital/Financing Update (CAP).
2018-11-04 Chinese
关于召开2018年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening an Extraordinary General Meeting (EGM) of shareholders for Betta Pharmaceuticals Co., Ltd. It includes information about the meeting date, agenda items for shareholder voting, voting procedures (both in-person and online), registration details, and proxy forms. The document does not contain financial statements or results but is focused on informing shareholders about the meeting and the proposals to be voted on. This matches the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings. The document length is about 5,000 characters, and it is the actual notice and materials, not just an announcement of a report publication. Therefore, the correct classification is PSI with high confidence.
2018-11-04 Chinese
独立董事关于第二届董事会第二十六次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the 26th meeting of the second board of directors of Betta Pharmaceuticals Co., Ltd. It discusses approval and opinions on financing by a subsidiary, changes in investment projects, and related party transactions. The content focuses on board-level decisions and opinions rather than financial results, earnings, or regulatory filings. It is not a full annual or interim report, nor an earnings release or audit report. The document is a formal board/management information disclosure related to governance and board meeting decisions. Therefore, it fits best under Board/Management Information (MANG). The document length is short (1526 characters), and it is not merely an announcement or certification, so it is not RPA or RNS.
2018-11-04 Chinese
中国国际金融股份有限公司关于公司变更募集资金投资项目的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed report from China International Capital Corporation Limited (the sponsor) regarding the change in the use of proceeds from the initial public offering (IPO) of Betta Pharmaceuticals Co., Ltd. It includes extensive financial data on the original and adjusted investment projects funded by the IPO proceeds, regulatory approvals, project feasibility, economic benefits, and opinions from the board, supervisory committee, independent directors, and the sponsor. The document is not a full annual or interim financial report, nor is it a simple announcement or certification. It focuses on the verification and opinion on changes to the use of IPO proceeds, which is a capital/financing update related to fundraising and investment project changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (9431 characters) and content support this classification with high confidence.
2018-11-04 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.